The regulatory setback stems from outstanding manufacturing observations at a third-party facility and incomplete final product labeling. The FDA issued an Official Action Indicated classification for the site, though the agency clarified that these general compliance issues are not specific to the production of cytisinicline.

Achieve plans to pivot its manufacturing strategy by designating Adare as its primary partner. This transition sets the stage for a new drug application resubmission in the fourth quarter of 2026. If the timeline holds, the company anticipates potential FDA approval in the first half of 2027, followed by a commercial launch in the United States. Cytisinicline, an alkaloid that binds to nicotinic acetylcholine receptors, remains a high-stakes candidate for treating both cigarette and e-cigarette nicotine addiction.